Enterovirus inhibitors

Infectious diseases

Current development stage

Discovery

Lead Gen

Lead Opt

Pre-clinical

Partnered/Clinical

CD3 and KU Leuven are developing broad-spectrum small-molecule antivirals against enteroviruses, especially human rhinoviruses, by inhibiting the viral protease.

Target
3Cpro
Therapeutic area
Infectious diseases
Disease
Enterovirus
Development Partner

Collaboration Opportunity

We are currently seeking a strategic partner for IND-enabling studies and Clinical Phase I development.